Baikal Skullcap (Scutellaria baicalensis) has a long history of use in traditional Chinese medicine, but its application for autoimmune disorders is increasingly being explored in scientific studies. The plant contains flavonoids such as baicalin and baicalein, which exhibit anti-inflammatory and immunomodulatory properties in preclinical research. Experimental models, including those for rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases, have shown that extracts from Baikal Skullcap can reduce inflammatory cytokine production and modulate immune responses. For example, baicalin has been found to inhibit NF-κB pathway activation, decrease T-cell proliferation, and suppress the differentiation of Th17 cells, which are implicated in autoimmune pathologies. However, most available evidence comes from in vitro studies and animal models; robust clinical trials in humans with autoimmune diseases are very limited or absent. As such, while there is a scientific rationale and some early evidence supporting its potential benefit for autoimmune disorders, the overall level of evidence is still preliminary. More rigorous human studies are needed to confirm efficacy and safety. Therefore, Baikal Skullcap's use in supporting autoimmune disorders is justified by emerging scientific research, but not yet strongly validated.